Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.
about
Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility.Causal inference and longitudinal data: a case study of religion and mental health.Cautionary tales in the interpretation of observational studies of effects of clinical interventions.The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.Body characteristics, [corrected] dietary protein and body weight regulation. Reconciling conflicting results from intervention and observational studies?Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studiesBody mass index, diabetes, and mortality in French women: explaining away a "paradox".Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular eventsIncident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation.Statins and venous thrombosis: a story too good to be true?The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study.Anti-hypertensive medications and cardiovascular events in older adults with multiple chronic conditions.Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficientComparison of the Efficacy of a Diabetes Education Programme for Type 1 Diabetes (PRIMAS) in a Randomised Controlled Trial Setting and the Effectiveness in a Routine Care Setting: Results of a Comparative Effectiveness Study.Bacterial composition in whole saliva from patients with severe hyposalivation--a case-control study.Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study.Counterpoint: epidemiology to guide decision-making: moving away from practice-free researchPoint: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology?Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fractionPotential bias in medication adherence studies of prevalent users.Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction.Association between statins and infections among patients with diabetes: a cohort and prescription sequence symmetry analysisInvited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes.Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failureStatin prescribing for people with severe mental illnesses: a staggered cohort study of 'real-world' impacts.Desideratum for evidence based epidemiology.Study design elements for rigorous quasi-experimental comparative effectiveness research.Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study.Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia.Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer.Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives.Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation.Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting.
P2860
Q30243926-7FCBDDC8-2A79-42FF-8340-960C9D842EA0Q30245348-9AC749F0-7426-4654-A45B-30C9B3BF213AQ30249320-D962A659-12A4-4DE5-95E9-D09473EC4D5EQ30875843-25C8F6D9-87C0-420F-962B-5D97B886E5ACQ33843231-FA504B5D-EBA1-4155-8903-EAB36E3AECBDQ33857564-1D52DFA3-0A22-45B1-A62B-D754E257C51BQ33986182-4D543975-C0CA-4CC4-9CC1-BC67FDDDD6A9Q34004440-61B51D05-FEEC-47F1-A8CB-5E12E7E73FE1Q34080023-F8FB77DC-1E58-4CDB-8F79-17898C989473Q34268703-E068716A-5D2C-4130-B283-2DD03314AC4AQ34426285-60B8094E-C86C-4CD9-BE0F-29A8C5FC26E3Q34476667-52C5BF07-9243-405B-9BBA-8E931471EE60Q35116408-AA3309DC-CCE0-4C5B-A37D-FCFC050FE65BQ35541348-B27C6BF2-2EEC-4192-BD2D-7872F1A9F927Q35901072-1DA9927B-41A9-419B-A1EC-169BB2911981Q35908544-A3598B14-D141-45C8-A8EB-735BCB2B8B40Q35977313-CA60D5E9-28EC-4101-8DA5-247245DC4A2FQ36251376-B9477D4D-1EA7-4CB2-BC90-C6DF9D95659CQ36251763-613FB175-53D6-493C-A0CD-F7FB283319D7Q36251771-F8296EE7-162F-4857-AA9F-8D30F9D290AEQ36635329-B02477E1-6D79-4BDC-9DA6-6F5872642AB2Q36675003-3F42F7F0-19D0-41A1-93AD-7A61F16F65D3Q36851454-173864CE-3429-4019-8385-617326EBEAB9Q36860117-908DFE6A-C77F-4DB9-9E13-5DFCA10A33C3Q36960602-C5359405-9115-49D6-B648-CE6CB6EE9B78Q37050974-95EBC8BD-E006-4DA7-9FB5-EACA7EF6700DQ37203236-E3FFD6F1-5E04-4540-A3CE-497A5F0FBA85Q37456365-8D47FB61-D09C-4D08-9331-928C11EF4F38Q37491134-CFE51DB5-9225-40D3-B860-2D13EFD8E4C5Q37594550-61D0039D-C754-4393-AA37-6D23158B7C9FQ37704226-099031ED-84DF-40BA-8B4D-9C07A4771256Q38156063-C2BB66EE-C125-4164-B845-A62B39EF5475Q38162881-4733ED82-B600-4167-9A09-F76E3237938BQ38211112-4246DE9B-7DCB-46EE-B81D-E8672397D968Q38419112-9880FC80-9750-4392-85EF-82705FF43062Q38617408-CECF553C-7A4F-4823-B451-2D3473502B47Q38691382-A43EEC86-3F73-48B8-A292-5ED8B6854DD0Q38801878-BD91CD22-51DC-46C9-95C1-882D85D695E3Q39709341-975554CF-E770-46E3-A4CD-5ED15C985F51Q40167819-81D4B899-3D9B-4695-A33C-26B18F2D3AF1
P2860
Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Bias in observational studies ...... om a meta-analysis of statins.
@ast
Bias in observational studies ...... om a meta-analysis of statins.
@en
type
label
Bias in observational studies ...... om a meta-analysis of statins.
@ast
Bias in observational studies ...... om a meta-analysis of statins.
@en
prefLabel
Bias in observational studies ...... om a meta-analysis of statins.
@ast
Bias in observational studies ...... om a meta-analysis of statins.
@en
P2093
P2860
P356
P1476
Bias in observational studies ...... om a meta-analysis of statins.
@en
P2093
Goodarz Danaei
Miguel A Hernán
Mohammad Tavakkoli
P2860
P304
P356
10.1093/AJE/KWR301
P407
P577
2012-01-05T00:00:00Z